BENDAMUSTINE

Search structure
Trade Names:
Synonyms:
Status: Approved (2008)
Entry Type: Small molecule
Molecule Category: Parent
ATC: L01AA09
UNII: 9266D9P3PQ

Structure
InChI Key YTKUWDBFDASYHO-UHFFFAOYSA-N
Smile Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21
InChI
InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H21Cl2N3O2
Molecular Weight 358.27
AlogP 3.26
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 9.0
Polar Surface Area 58.36
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 23.0

Pharmacology

Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 49

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 3 D015451 ClinicalTrials
Lymphoma, Mantle-Cell 3 D020522 ClinicalTrials
Lymphoma, Non-Hodgkin 3 D008228 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Immunoblastic Lymphadenopathy 3 D007119 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Amyloidosis, Familial 2 D028226 ClinicalTrials
Lymphoma, T-Cell, Peripheral 2 D016411 ClinicalTrials
Waldenstrom Macroglobulinemia 2 D008258 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Lymphoma, B-Cell, Marginal Zone 2 D018442 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Lymphoma, B-Cell, Marginal Zone 2 D018442 ClinicalTrials
Leukemia, Hairy Cell 2 D007943 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials
Myelodysplastic Syndromes 1 D009190 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 D015464 ClinicalTrials
Leukemia, Plasma Cell 1 D007952 ClinicalTrials

Related Entries

MCS

Salt

Side Effects from Label

Side effects Relative Frequency (%) Labels
Investigations Lymphocyte count decreased 99.0
Investigations Lymphocyte count decreased 94.0
Investigations White blood cell count decreased 94.0
Investigations Haemoglobin decreased 89.3
Investigations Haemoglobin decreased 88.0
Blood and lymphatic system disorders Neutropenia 86.0
Investigations Platelet count decreased 86.0
Investigations Haemoglobin decreased 81.6
Investigations Platelet count decreased 78.0
Investigations Platelet count decreased 77.3
Blood and lymphatic system disorders Neutropenia 75.3
Gastrointestinal disorders Nausea 75.0
Investigations Lymphocyte count decreased 68.0
Investigations White blood cell count decreased 61.3
Blood and lymphatic system disorders Neutropenia 61.0
Blood and lymphatic system disorders Neutropenia 60.0
General disorders and administration site conditions Asthenia 57.0
General disorders and administration site conditions Fatigue 57.0
Investigations White blood cell count decreased 56.0
Investigations Lymphocyte count decreased 46.7
Blood and lymphatic system disorders Neutropenia 43.3
Gastrointestinal disorders Vomiting 40.0
Gastrointestinal disorders Diarrhoea 37.0
Investigations Body temperature increased 34.0
Blood and lymphatic system disorders Neutropenia 28.0
Investigations White blood cell count decreased 28.0
Investigations Platelet count decreased 25.0
Investigations Body temperature increased 24.0
Investigations Body temperature increased 23.5
Blood and lymphatic system disorders Thrombocytopenia 23.0
Blood and lymphatic system disorders Neutropenia 21.3
Gastrointestinal disorders Nausea 20.3
Gastrointestinal disorders Nausea 20.0
Investigations Lymphocyte count decreased 19.1
Blood and lymphatic system disorders Anaemia 19.0
Investigations White blood cell count decreased 18.4
Blood and lymphatic system disorders Leukopenia 18.0
Gastrointestinal disorders Vomiting 16.0
Gastrointestinal disorders Vomiting 15.7
Gastrointestinal disorders Nausea 14.7
Investigations Haemoglobin decreased 13.3
General disorders and administration site conditions Asthenia 11.0
General disorders and administration site conditions Fatigue 11.0
Investigations Haemoglobin decreased 11.0
Investigations Platelet count decreased 10.7
Investigations Platelet count decreased 9.93
General disorders and administration site conditions Asthenia 9.15
Gastrointestinal disorders Diarrhoea 9.15
General disorders and administration site conditions Fatigue 9.15
Investigations Haemoglobin decreased 8.51
General disorders and administration site conditions Asthenia 8.5
Infections and infestations Nasopharyngitis 8.39
Skin and subcutaneous tissue disorders Dermatitis 7.84
Skin and subcutaneous tissue disorders Rash 7.84
Investigations Blood uric acid increased 7.19
Metabolism and nutrition disorders Hyperuricaemia 7.19
Investigations Weight decreased 7.19
Infections and infestations Nasopharyngitis 6.54
Gastrointestinal disorders Vomiting 6.29
Blood and lymphatic system disorders Febrile neutropenia 6.0
General disorders and administration site conditions Chills 5.88
Infections and infestations Infection 5.88
General disorders and administration site conditions Asthenia 5.59
Investigations Body temperature increased 5.59
General disorders and administration site conditions Fatigue 5.59
Skin and subcutaneous tissue disorders Pruritus 5.23
Respiratory, thoracic and mediastinal disorders Cough 4.9
Skin and subcutaneous tissue disorders Dermatitis 4.9
Infections and infestations Herpes simplex 4.9
Skin and subcutaneous tissue disorders Rash 4.9
Immune system disorders Hypersensitivity 4.58
Investigations Lymphocyte count decreased 4.26
General disorders and administration site conditions Asthenia 4.2
Investigations Body temperature increased 3.92
Respiratory, thoracic and mediastinal disorders Cough 3.92
Gastrointestinal disorders Diarrhoea 3.5
Investigations Weight decreased 3.5
Infections and infestations Herpes simplex 3.27
Endocrine disorders Hyperglycaemia 3.0
Investigations White blood cell count decreased 2.84
Skin and subcutaneous tissue disorders Dermatitis 2.61
Skin and subcutaneous tissue disorders Rash 2.61
Skin and subcutaneous tissue disorders Dermatitis 2.1
Immune system disorders Hypersensitivity 2.1
Skin and subcutaneous tissue disorders Rash 2.1
Investigations Blood creatinine increased 2.0
Immune system disorders Hypersensitivity 2.0
Metabolism and nutrition disorders Hypocalcaemia 2.0
Metabolism and nutrition disorders Hyponatraemia 2.0
Investigations Blood uric acid increased 1.96
Metabolism and nutrition disorders Hyperuricaemia 1.96
Infections and infestations Infection 1.96
Investigations Blood uric acid increased 1.4
Investigations Body temperature increased 1.4
Metabolism and nutrition disorders Hyperuricaemia 1.4
Skin and subcutaneous tissue disorders Pruritus 1.4
General disorders and administration site conditions Asthenia 1.31
Gastrointestinal disorders Diarrhoea 1.31
General disorders and administration site conditions Fatigue 1.31
Immune system disorders Hypersensitivity 1.31
Investigations Body temperature increased 1.0
General disorders and administration site conditions Chills 0.699
Respiratory, thoracic and mediastinal disorders Cough 0.699
Infections and infestations Infection 0.699
Gastrointestinal disorders Nausea 0.699
Respiratory, thoracic and mediastinal disorders Cough 0.654
Gastrointestinal disorders Nausea 0.654
Gastrointestinal disorders Vomiting 0.654

Cross References

Resources Reference
CAS NUMBER 16506-27-7
ChEBI 135515
ChEMBL CHEMBL487253
DrugBank DB06769
DrugCentral 302
EPA CompTox DTXSID2046888
FDA SRS 9266D9P3PQ
Guide to Pharmacology 7478
PubChem 65628
SureChEMBL SCHEMBL26319
ZINC ZINC000004214955
CONTENTS